Evidence map›Paper›PMID 26478855›Full record

ArticleCurrent pharmacology reports2015

Resveratrol and Malignancies.

Rodica P Bunaciu, Andrew Yen

Open access · bronzeAbstract read
In one paragraph

Article in Current pharmacology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rodica P BunaciuDepartment of Biomedical Sciences, Cornell University, Ithaca, NY, 14853, USA.
Andrew YenDepartment of Biomedical Sciences, Cornell University, Ithaca, NY, 14853, USA.
Cornell University · US

Funding

TRANS-NETWORK PROJECTSU54CA143876 · NCI · CORNELL UNIVERSITY · PI SHULER, MICHAEL L · 2009 to 2014
$12.6M
NUTRITIONAL CELL CYCLE AND DIFFERENTIATION CONTROLR01CA033505 · NCI · UNIVERSITY OF IOWA · PI YEN, ANDREW · 1985 to 2013
$3.2M
Mechanism of Action of Retinoic Acid Using CD38R01CA152870 · NCI · CORNELL UNIVERSITY · PI HAO, QUAN, LIN, HENING · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA033505NCI NIH HHS R01 CA152870NCI NIH HHS U54 CA143876
6 · The paper itself

Abstract

Carcinogenesis is a multifactorial process, frequently encompassing 3 stages: initiation, promotion and progression. It is characterized by multiple deviations from normal both at the cell and organism levels. Although most people have a small number of cells that present deviations from normal, most of those cells will not cause cancer. However, some will. What tips the balance between normal and abnormal is the subject of intense scientific research as well as unfounded speculations. Chronic inflammation is one of the risk factors for cancer. Resveratrol is consumed by the population as a dietary supplement in the hope of decreasing the risk of inflammation and cancer and other chronic diseases such as diabetes and vascular diseases. There is a discrepancy between the doses used in the animal studies showing that resveratrol decreases all three stages of carcinogenesis, and the doses ingested by the population either as supplements or in the diet. While there is health benefit from using high resveratrol doses, it might be also of practical and scientific benefit to focus future effort in understanding the effects of normal dietary resveratrol levels.

Indexed as

3,4′,5-Trihydroxy-trans-stilbene5-[(1E)-2-(4-Hydroxyphenyl) ethenyl]-1,3-benzenediolcancerhumanResveratrolStilbene

Identifiers

PMID26478855
PMCPMC4607076
OpenAlexW2022433447

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.